ArticleRSC advances2026
Gingerol-loaded hollow manganese dioxide nanoparticles attenuate intervertebral disc oxidative stress.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) is a major cause of chronic low back pain, thus therapies capable of halting its progression are urgently needed. Evidence suggests that oxidative stress is a key accelerator of IVDD, making interventions targeting reactive oxygen species (ROS) highly promising. The natural compound 6-gingerol has been proved to possess potent antioxidant properties, however, its therapeutic application is hampered by poor solubility, rapid clearance, and lack of targeted delivery. To address these limitations and investigate the effect of 6-gingerol on IVDD, we developed an integrated nanoplatform (H@G) by encapsulating 6-gingerol within hollow manganese dioxide nanoparticles. The synthesized H@G nanoparticles exhibited a uniform hollow spherical structure (∼100 nm), a high surface area, and successful drug loading without altering the carrier morphology. The nanoparticles demonstrated good stability in physiological media but underwent rapid degradation under acidic conditions and in an H
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.